EICHORCondition: Urinary Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Urological Associates of Southern Arizona, P.C. | Tucson, Arizona, United States | — |
| UAMS Winthrop P. Rockefeller Cancer Institute | Little Rock, Arkansas, United States | — |
| Arkansas Urology | Little Rock, Arkansas, United States | — |
| City of Hope | Duarte, California, United States | — |
| Genesis Research | San Diego, California, United States | — |
| Colorodo Urology- St. Anthony Hospital | Golden, Colorado, United States | — |
| University of Florida Health Jacksonville | Jacksonville, Florida, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Baptist Hospital of Miami | Miami, Florida, United States | — |
| Winship Cancer Institute Emory University | Atlanta, Georgia, United States | — |
| DuPage Medical Group | Lisle, Illinois, United States | — |
+ 97 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04919512